New Drug Shows Promise in Slowing Alzheimer's Symptoms
TEHRAN (Tasnim) – International pharmaceutical company Eli Lilly revealed promising results from its Phase 3 donanemab trials, indicating that the drug significantly slowed cognitive and functional decline in participants with early Alzheimer's.
